company background image
AUTL

Autolus TherapeuticsNasdaqGS:AUTL Stock Report

Market Cap

US$456.5m

7D

0.6%

1Y

-34.9%

Updated

26 Nov, 2021

Data

Company Financials +
AUTL fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

AUTL Stock Overview

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer.

Autolus Therapeutics Competitors

Precigen

NasdaqGS:PGEN

US$798.0m

Price History & Performance

Summary of all time highs, changes and price drops for Autolus Therapeutics
Historical stock prices
Current Share PriceUS$6.26
52 Week HighUS$12.23
52 Week LowUS$4.60
Beta1.55
1 Month Change11.79%
3 Month Change-7.81%
1 Year Change-34.86%
3 Year Change-83.96%
5 Year Changen/a
Change since IPO-74.96%

Recent News & Updates

Jul 20

Autolus: Developing Better CAR-T In Refractory ALL

AUTL is a UK-based developer of CAR-T. It claims a better tax profile than Tecartus in adult r/r ALL. Price is currently depressed.

Shareholder Returns

AUTLUS BiotechsUS Market
7D0.6%0.4%-2.7%
1Y-34.9%5.3%21.3%

Return vs Industry: AUTL underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: AUTL underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is AUTL's price volatile compared to industry and market?
AUTL volatility
AUTL Average Weekly Movement10.6%
Biotechs Industry Average Movement8.6%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: AUTL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: AUTL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2014380Chris Itinhttps://www.autolus.com

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics Fundamentals Summary

How do Autolus Therapeutics's earnings and revenue compare to its market cap?
AUTL fundamental statistics
Market CapUS$456.47m
Earnings (TTM)-US$143.29m
Revenue (TTM)US$2.55m

178.8x

P/S Ratio

-3.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AUTL income statement (TTM)
RevenueUS$2.55m
Cost of RevenueUS$133.88m
Gross Profit-US$131.33m
ExpensesUS$11.96m
Earnings-US$143.29m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.97
Gross Margin-5,142.05%
Net Profit Margin-5,610.45%
Debt/Equity Ratio0%

How did AUTL perform over the long term?

See historical performance and comparison

Valuation

Is Autolus Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AUTL ($6.26) is trading below our estimate of fair value ($69.49)

Significantly Below Fair Value: AUTL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AUTL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: AUTL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AUTL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AUTL is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Autolus Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

27.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AUTL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AUTL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AUTL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AUTL's revenue (74.6% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: AUTL's revenue (74.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AUTL is forecast to be unprofitable in 3 years.


Past Performance

How has Autolus Therapeutics performed over the past 5 years?

-38.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AUTL is currently unprofitable.

Growing Profit Margin: AUTL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AUTL is unprofitable, and losses have increased over the past 5 years at a rate of 38.2% per year.

Accelerating Growth: Unable to compare AUTL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AUTL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: AUTL has a negative Return on Equity (-58.55%), as it is currently unprofitable.


Financial Health

How is Autolus Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AUTL's short term assets ($237.7M) exceed its short term liabilities ($34.6M).

Long Term Liabilities: AUTL's short term assets ($237.7M) exceed its long term liabilities ($17.3M).


Debt to Equity History and Analysis

Debt Level: AUTL is debt free.

Reducing Debt: AUTL has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AUTL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: AUTL has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 31.5% each year.


Dividend

What is Autolus Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AUTL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AUTL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AUTL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AUTL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AUTL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Chris Itin (57 yo)

5.67yrs

Tenure

US$4,255,196

Compensation

Dr. Christian Martin Itin, also known as Chris, Ph D., has been the Chief Executive Officer of Autolus Therapeutics Plc. (Former Name: Autolus Limited) since March 3, 2016.Dr. Itin has been Director of Au...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD4.26M) is above average for companies of similar size in the US market ($USD1.70M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: AUTL's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: AUTL's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.4%.


Top Shareholders

Company Information

Autolus Therapeutics plc's employee growth, exchange listings and data sources


Key Information

  • Name: Autolus Therapeutics plc
  • Ticker: AUTL
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$456.473m
  • Shares outstanding: 72.92m
  • Website: https://www.autolus.com

Number of Employees


Location

  • Autolus Therapeutics plc
  • Forest House
  • 58 Wood Lane
  • London
  • Greater London
  • W12 7RZ
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 23:02
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.